ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Capecitabine

Also written as “capecitabine”, “capecitabine [Xeloda]” and “Utidelone in combination with capecitabine”.

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Neoplasms, led by 13 companies.

Drug pageCapecitabine: every studyMany companies study it; this page follows only the 72 they lead. All 947 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 12, 200472 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only430 open or runningphase 4since Jul 12, 2004May 2, 2000none ahead
Sanofiits history only90 open or runningphase 3since Apr 20, 2004Apr 20, 2004none ahead
R-Pharmits history only60 open or runningphase 3since Mar 26, 2004Nov 12, 2002none ahead
Novartisits history only41 open or runningphase 3since Jul 26, 2007Jul 26, 2007Apr 14, 2027phase 2 · NCT06247995
Qilu Pharmaceuticalits history only21 open or runningphase 2since Jun 1, 2024Feb 10, 2018none ahead
Academy Military Medical Science, Chinaits history only10 open or runningphase 2since Jul 14, 2008Jul 14, 2008none ahead
Bio-Cancer Treatment Internationalits history only10 open or runningphase 2since Mar 14, 2014Mar 14, 2014none ahead
EBG MedAustronits history only11 open or runningno phasesince May 10, 2021May 10, 2021Dec 31, 2026NCT04894643
iOMEDICOits history only10 open or runningphase 4since Aug 28, 2014Aug 28, 2014none ahead
NovoCureits history only10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead
Pharmatech Oncology10 open or runningphase 2since Nov 9, 2001Nov 9, 2001none ahead

Also a collaborator on its studies: Exelixis, Clovis Oncology, Johnson & Johnson, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Zai Lab, Chengdu Biostar Pharmaceuticals, Regeneron Pharmaceuticals, GlaxoSmithKline and Yakult Honsha.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pharmatech Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2001First study: phase 2 study in Breast NeoplasmsFirst studyNCT00026442 · United States

TargetBeta

TYMS →read by rule
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Other programs on TYMS

ProgramCompanyFurthest phaseStudies
PemetrexedruleEli Lillyphase 4141
FluorouracilruleSanofiphase 482
TegafurruleOtsukaphase 325

Studies

The one study Pharmatech Oncology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00026442Breast Neoplasms · United States2UNKNOWN

How it is read

Names in the registry

  • “Capecitabine”, 62 entries
  • “capecitabine”, 16 entries
  • “capecitabine [Xeloda]”, 12 entries
  • “Utidelone in combination with capecitabine”, 3 entries
  • “Capecitabine [Xeloda]”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.